J Rheum Dis.  2022 Jul;29(3):129-131. 10.4078/jrd.2022.29.3.129.

Importance of Time-integrated Cumulative Parameters for Radiographic Progression Prediction of Rheumatoid Arthritis

• Park DJ

• KMID: 2530676
• DOI: http://doi.org/10.4078/jrd.2022.29.3.129

Reference

1. Scott DL, Wolfe F, Huizinga TW. 2010; Rheumatoid arthritis. Lancet. 376:1094–108. DOI: 10.1016/S0140-6736(10)60826-4.

2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010; 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62:2569–81. DOI: 10.1002/art.27584. PMID: 20872595.

3. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. 2008; Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58:15–25. DOI: 10.1002/art.23177. PMID: 18163481.

4. Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W. 2009; The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes. 7:25. DOI: 10.1186/1477-7525-7-25. PMID: 19296831. PMCID: PMC2674445.

5. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2016; 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 68:1–25. DOI: 10.1002/acr.22783. PMID: 26545825.

6. Pope J, Sawant R, Tundia N, Du EX, Qi CZ, Song Y, et al. 2020; Comparative efficacy of JAK inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis. Adv Ther. 37:2356–72. DOI: 10.1007/s12325-020-01303-3. PMID: 32297280. PMCID: PMC7467453.

7. van der Heijde D, Landewé R. 2018; Should radiographic progression still be used as outcome in RA? Clin Immunol. 186:79–81. DOI: 10.1016/j.clim.2017.07.022. PMID: 28743593.

8. van der Heijde D. 2001; Radiographic progression in rheumatoid arthritis: does it reflect outcome? Does it reflect treatment? Ann Rheum Dis. 60 Suppl 3:iii47–50.

9. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021; 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 73:1108–23. DOI: 10.1002/art.41752. PMID: 34101376.

10. Landewé R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. 2006; Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum. 54:3119–25. DOI: 10.1002/art.22143. PMID: 17009230.

11. Ten Klooster PM, Versteeg LGA, Oude Voshaar MAH, de la Torre I, De Leonardis F, Fakhouri W, et al. 2019; Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Arthritis Res Ther. 21:237. DOI: 10.1186/s13075-019-2030-8. PMID: 31718678. PMCID: PMC6852758.

12. Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML, et al. 2012; Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis. 71:681–6. DOI: 10.1136/ard.2011.154625. PMID: 21994234.

13. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. 2006; Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 54:3761–73. DOI: 10.1002/art.22190. PMID: 17133543.

14. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, et al. 2008; An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 58:2958–67. DOI: 10.1002/art.23945. PMID: 18821687.

15. Pope JE, Choy EH. 2021; C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum. 51:219–29. DOI: 10.1016/j.semarthrit.2020.11.005. PMID: 33385862.

16. Chiu WC, Lai HM, Ko CH, Chen JF, Hsu CY, Chen YC. 2018; Ultrasound is more reliable than inflammatory parameters to evaluate disease activity in patients with RA receiving tocilizumab therapy. J Investig Med. 66:1015–8. DOI: 10.1136/jim-2017-000705. PMID: 29581384. PMCID: PMC6073910.

17. Walker UA, Mueller RB, Jaeger VK, Theiler R, Forster A, Dufner P, et al. 2017; Disease activity dynamics in rheumatoid arthritis: patients' self-assessment of disease activity via WebApp. Rheumatology (Oxford). 56:1707–12. DOI: 10.1093/rheumatology/kex229. PMID: 28957553. PMCID: PMC5873216.

18. Park Y, Li ML, Kim JW, Koh JH, Park YJ, Kim WU. 2022; Time-integrated cumulative parameters predictive of radiographic progression of rheumatoid arthritis: real-world data from a prospective single-center cohort. J Rheum Dis. 29:98–107. DOI: 10.4078/jrd.2022.29.2.98.

19. Welsing PM, Landewé RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. 2004; The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum. 50:2082–93. DOI: 10.1002/art.20350. PMID: 15248205.

20. Svensson B, Andersson ML, Bala SV, Forslind K, Hafström I. BARFOT study group. 2013; Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria. BMJ Open. 3:e003554. DOI: 10.1136/bmjopen-2013-003554. PMID: 24022393. PMCID: PMC3773654.